PubMed

Unboosted fosamprenavir is associated with low drug exposure in HIV-infected patients with mild-moderate liver impairment resulting from HCV-related cirrhosis.

Gatti F, Nasta P, Loregian A, Puoti M, Matti A, Pagni S, de Requena DG, Prestini K, Parisi SG, Bonora S, Palù G, Carosi G.

J Antimicrob Chemother. 2009 Mar;63(3):575-8. Epub 2009 Jan 16.PMID: 19151039 [PubMed - indexed for MEDLINE]Related articles

Pharmacokinetic and pharmacodynamic determinants of early virological response to enfuvirtide-based regimens in HIV-positive patients.

de Requena DG, Bonora S, Castagna A, Hasson H, Marucco DA, D'Avolio A, Sciandra M, Trentini L, Calcagno A, Lazzarin A, Di Perri G.

J Antimicrob Chemother. 2008 Aug;62(2):384-7. Epub 2008 May 16.PMID: 18487231 [PubMed - indexed for MEDLINE]Related articlesFree article

Does iatrogenic scleroderma due to injection-site reaction to enfuvirtide impair absorption of the drug?

Maggi P, Filotico R, Bonora S, Volpe A, Bellacosa C, Cinori E, de Requena DG, D'Avolio A, Di Perri G.

Clin Drug Investig. 2008;28(5):305-11. Review.PMID: 18407716 [PubMed - indexed for MEDLINE]Related articles

Tipranavir (TPV) genotypic inhibitory quotient predicts virological response at 48 weeks to TPV-based salvage regimens.

de Requena DG, Bonora S, Calcagno A, D'Avolio A, Siccardi M, Fontana S, Milia MG, Sciandra M, Garazzino S, Di Garbo A, Baietto L, Trentini L, Di Perri G.

Antimicrob Agents Chemother. 2008 Mar;52(3):1066-71. Epub 2007 Dec 26.PMID: 18160524 [PubMed - indexed for MEDLINE]Related articlesFree article

A simple and sensitive assay for determining plasma tipranavir concentration in the clinical setting by new HPLC method.

D'Avolio A, Sciandra M, Siccardi M, Baietto L, de Requena DG, Bonora S, Di Perri G.

J Chromatogr B Analyt Technol Biomed Life Sci. 2007 Apr 1;848(2):374-8. Epub 2006 Nov 7.PMID: 17092784 [PubMed - indexed for MEDLINE]Related articles

Validation of liquid/liquid extraction method coupled with HPLC-UV for measurement of ribavirin plasma levels in HCV-positive patients.

D'Avolio A, Ibañez A, Sciandra M, Siccardi M, de Requena DG, Bonora S, Di Perri G.

J Chromatogr B Analyt Technol Biomed Life Sci. 2006 May 1;835(1-2):127-30. Epub 2006 Mar 29.PMID: 16569520 [PubMed - indexed for MEDLINE]Related articles

An improved HPLC fluorimetric method for the determination of enfuvirtide plasma levels in HIV-infected patients.

D'Avolio A, Sciandra M, de Requena DG, Ibañez A, Bonora S, Di Perri G.

Ther Drug Monit. 2006 Feb;28(1):110-5.PMID: 16418704 [PubMed - indexed for MEDLINE]Related articles

Changes in nevirapine plasma concentrations over time and its relationship with liver enzyme elevations.

De Requena DG, Jiménez-Nácher I, Soriano V.

AIDS Res Hum Retroviruses. 2005 Jun;21(6):555-9.PMID: 15989460 [PubMed - indexed for MEDLINE]Related articles

Does an increase in nevirapine plasma levels cause complete virologic suppression in patients experiencing early virologic failure?

de Requena DG, Núñez M, Gallego O, Jiménez-Nácher I, González-Lahoz J, Soriano V.

HIV Clin Trials. 2002 Nov-Dec;3(6):463-7.PMID: 12501129 [PubMed - indexed for MEDLINE]Related articlesFree article

Impact of HIV genotyping and drug levels on the response to salvage therapy with saquinavir/ritonavir.

Valer L, De Mendoza C, De Requena DG, Labarga P, García-Henarejos A, Barreiro P, Guerrero F, Vergara A, Soriano V; Fortogene Spanish Study Group.

AIDS. 2002 Sep 27;16(14):1964-6. No abstract available. PMID: 12351959 [PubMed - indexed for MEDLINE]Related articles